The expression of the c-erbB-2 mRNA in human embryonic lung fibroblasts, a gastric cancer cell line, mature placenta, and 25 gastric cancer tissues was examined by using the polymerase chain reaction following reverse transcription. This technique can be used to examine c-erbB-2 mRNA expression in a small endoscopic biopsy specimen before surgery.
Summary
The expression of the c-erbB-2 mRNA in human embryonic lung fibroblasts, a gastric cancer cell line, mature placenta, and 25 gastric cancer tissues was examined by using the polymerase chain reaction following reverse transcription. This technique can be used to examine c-erbB-2 mRNA expression in a small endoscopic biopsy specimen before surgery.
To examine the genetic alterations of early stage cancer or the phenotypic changes is very important for the elucidation of malignant transformation and prediction of prognosis. The human c-erbB-2 proto-oncogene is identified based on close sequence homology in the tyrosine kinase domain to the v-erbB and EGF receptor (Coussens et al., 1985; Yamamoto et al., 1985) . Interestingly, c-erbB-2 gene amplification has been predominantly detected in carcinomas of glandular epithelial origin, including mammary (King et al., 1985) , salivary gland (Semba et al., 1985) , gastric and colon tumours (Yokota et al., 1986) . Increased expression of this proto-oncogene product has gained clinical interest from the observation that amplification of this gene in breast carcinomas might be related to poor prognosis (Slamon et al., 1987; Zhou et al., 1987) . In addition, an immunohistochemical study on paraffin embedded tissue has shown that overexpression of the c-erbB-2 gene might be associated with poor prognosis in breast (Berger et al., 1988) , ovarian (Berchuck et al., 1990) , and gastric cancers (Yonemura et al., 1991) . However, there were no suitable techniques to examine the genetic alteration of early stage cancer or phenotypic change. Recently, analytical techniques for mRNA expression have been developed by PCR following reverse transcription (RT-PCR) (Rappolee et al., 1988; Chelly et al., 1988; Kawasaki et al., 1988; Kashani-Sabet et al., 1988) . In this study, we could specifically detect the expression of the c-erbB-2 gene derived from a small amount of human gastric cancer specimens by RT-PCR, and found this method was sensitive and quantitative enough for analysis of c-erbB-2 gene expression of gastric cancer patients before surgery.
Materials and methods
Specific oligonucleotide primers for c-erbB-2 amplification were selected from the phosphorylation domain, containing extensive differences in length and primary structure between members of the human EGF receptor-related gene such as the EGF receptor gene and the c-erbB-3 gene (Kraus et al., 1989; Plowman et al., 1990) . The P-actin mRNA chosen as an internal control was also transcribed and amplified. The sence c-erbB-2 primer, ERB-2 (5'-GATGTATTTGATGGT-GACCT-3') corresponds to the c-erbB-2 cDNA sequence (3424-3443), represents the anti-sense strand of the c-erbB-2 cDNA sequence (3587-3606). The sence P-actin primer P-ACT-4 (5'-ATCACCATTGGCAATGAGCG-3') corresponds to the Pactin cDNA sequence (2233) (2234) (2235) (2236) (2237) (2238) (2239) (2240) (2241) (2242) (2243) (2244) (2245) (2246) (2247) (2248) (2249) (2250) (2251) (2252) . ,3-ACT-5 (5'-TTGAAG-GTAGTTTCGTGGAT-3') represents the anti-sense strand of the P-actin cDNA sequence (2406) (2407) (2408) (2409) (2410) (2411) (2412) (2413) (2414) (2415) (2416) (2417) (2418) (2419) (2420) (2421) (2422) (2423) (2424) (2425) . With the use of oppositely oriented primers, the 183 bp region of the c-erbB-2 gene or 93 bp region of the P-actin gene was amplified, flanked by the 2 oligomers. ERB-1 (5'-ACCCCAGCCCTC-TACAGCGGTACAGTGAGG-3') corresponding to c-erbB-2 cDNA (3488-3517) or 13-ACT-6 (5'-TGAGGCACTCTTC-CAGCCTT-3') corresponding to P-actin cDNA (2265 cDNA ( -2284 was used as the probe to detect the amplified c-erbB-2 or P-actin PCR products. Total RNA was extracted from human embryonic lung (HEL) fibroblasts, human gastric cancer cells (MKN-7), human gastric cancer tissues, and mature human placenta as described previously (Chomczynski & Sacci, 1987) .
A precise dilution series of the template RNA was prepared using yeast RNA to adjust the total to 1 jig. One jig of each total RNA from HEL, MKN-7, placenta and gastric carcinoma tissues was denatured by heated 95°C for 5 min and chilled on ice. Each sample was incubated in a total volume of 20 jil reaction mixture consisting of 1 x amplification buffer [10 mM Tris-HCI (pH 8.3), 50 mM KCI, Results and discussion First, the PCR amplified products from serial dilutions of HEL and MKN-7 total RNA were analysed by Southern blotting (Figures la and b) . In addition, a duplicate PCR assay of each RNA sample omitting reverse transcriptase was run to confirm that the hybridisation signal was the result from RNA and not DNA specific amplification. These results in Figure 1 indicate that the PCR products amplified with the primers, ERB-2 and ERB-3, could be detected at the concentration of 3 4' g (12 ng) to HEL total RNA. On the other hand, the PCR products from MKN-7 was detectable even at 10-4 fg (100 pg) of total RNA. The same sample did not produce any PCR-amplified fragments in the absence of reverse transcriptase. Radioactivity of PCR products hybridised with specific probes was measured by a Fujix BioImage analyser (Fuji Photo Film Co., Ltd., Tokyo). The 162 oX174/HincIl digest amount of radioactivity was plotted against the template concentration ( Figure 2 ). The PCR products were accumulated linearly to the template concentration. The amplified rates of MKN-7 and HEL were identical within the exponential phase of the PCR and that demonstrated the precise measurement of this method. Comparison of the hybridisation signal intensities between HEL and MKN-7 suggested that c-erbB-2 mRNA was overexpressed 72.6-fold in relative to HEL. However, the expression level of the P-actin mRNA between MKN-7 and HEL was the same.
Second, total RNA from six cases of surgically resected gastric cancer tissues and mature placenta were tested by the RT-PCR assay. PCR amplified products were analysed by Southern blotting and the hybridisation signals from gastric cancers were compared with that from placenta. As shown in Figure 3 aThe relative amount ratio ofPCR products in clinical samples to that in placenta was calculated with a curve in which radioactivities of PCR products were plotted against total RNA as template, as presented in Figure 3b for c-erbB-2. 'The relative amounts of c-erbB-2 mRNA were standardised by that of P-actin as an internal control. cc-erbB-2 protein immunoreactivity was classified into three groups (-, no staining; +, weak staining; + +, strong staining).
were standardised by that of P-actin mRNA as internal control. The c-erbB-2 mRNA overexpression in the case of D.T. was estimated to be 22.8-fold to placenta (Table IA) . Third, using a polyclonal antibody that is monospecific for the c-erbB-2 oncogene product, an immunohistochemical study on formalin-fixed paraffin-embedded tissue of these six gastric cancers was done for detecting the expression of c-erbB-2 protein. Among six cases, intense reactivity to this antibody was observed only in the case of D.T. (Table IA) . More 19 (cases) of surgically resected gastric cancer including one early cancer were examined expression level of c-erbB-2 mRNA by using RT-PCR assay and immunohistochemical assay (Table IB) . Overexpression of a 1.7 to 22.8 fold c-erbB-2 mRNA to placenta was found in four (16%) of 25 gastric cancers, while c-erbB-2 oncoprotein expression was found in only three cases by immunohistochemical assay. It seems that detection of c-erbB-2 gene products by using immunohistochemical assay is limited to a case in which the oncoprotein is expressed over about 2-fold to placenta. In this study, the RT-PCR assay was sensitive and quantitative enough for analysis of gene expression from a small amount of total RNA. Also, the expression level of c-erbB-2 was consistent with the results of immunohistochemical examination. This technique may be useful in examining the expression of c-erbB-2 gene when the usual analysis is not possible for lack of sufficient tumour tissue. The analysis of the activated oncogenes using this RT-PCR assay may be a good approach to elucidate the basic role of oncogenes in malignant transformation.
